According to a Blog Published by MSD Manual Growth Hormone Deficiency Affects 1 in Every 4,000 Children, which in Turn Led to Occurrence of Early Pubertal Symptoms

According to the report published in April, 2017 entitled ”Investigating the relationship between precocious puberty and obesity: a cross-sectional study in Shanghai, China”, this has been founded that out of the total population 25.98% of obese boys had central precocious puberty and 13.86% of obese girls had precocious puberty.  As per the publication of NCBI, published on October 2017, entitled “Association between Obesity and Puberty Timing: A Systematic Review and Meta-Analysis”, this has been proved that obesity is one of major cause of central precocious puberty.      

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-central-precocious-puberty-cpp-treatment-market

Global central precocious puberty (CPP) treatment market is expected to reach Euros 726.75 million by 2027 from Euros 425.76 million in 2019 growing with the substantial CAGR of 7.1% in the forecast period of 2020 to 2027. The central precocious puberty (CPP) treatment market is growing due to increasing cases of granulosa cell tumors, increasing global healthcare expenditure, favorable government support for product approval among others. The central precocious puberty (CPP) treatment market will grow in the forecast period due to presence of strong product pipeline, launch of awareness campaign and availability of off label drugs.           

Growing prevalence of hormonal disorders and increasing prevalence of obesity across the world will drive the market's growth rate

The number of children suffering from hormonal disorders is increasing due to several types of inherited factors and insufficient functioning of endocrine glands. These hormonal disorders mainly growth hormone disorder led the children to adopt early puberty symptoms which retards the height and other growth phenomenon in children. As the prevalence of growth hormone deficiency is increasing, children are more likely to attain precocious puberty. This suggests that growing prevalence of hormonal disorders expected to drive the central precocious puberty (CPP) treatment market growth.

Report Scope and Market Segmentation

Segment Analysis:

Global central precocious puberty (CPP) treatment market is categorized into six notable segments, which are based on the basis of type, month, route of administration, gender, end-user and distribution channel.

• On the basis of type, the central precocious puberty (CPP) treatment market is segmented into medication and surgery. In 2020, medication segment is expected to dominate the central precocious puberty (CPP) treatment market with 83.29% market share because of children with CPP, with no underlying serious conditions can be effectively treated with medication and medication is the first choice for the management and treatment of CPP. 
• On the basis of month, the central precocious puberty (CPP) treatment market is segmented into 1-month, 3-month, 6-month and others. In 2020, 1-month segment is expected to dominate the central precocious puberty (CPP) treatment market with 38.47% market share because after a child diagnosed with CPP, initial treatment were given for one month to monitor the effect of the treatment.
• On the basis of route of administration, the central precocious puberty (CPP) treatment market is segmented into parenteral, oral, implants, and others. In 2020, parenteral segment is expected to dominate the central precocious puberty (CPP) treatment market with 56.13% market share because of drugs used for CPP treatment which have the sustained release formulation and continuous prolonged administration (injectables) of GnRH required.
• On the basis of gender, the central precocious puberty (CPP) treatment market is segmented into girls and boys. In 2020, girls segment is expected to dominate the central precocious puberty (CPP) treatment market with 72.41% market share since the CPP is less common in boys as compared to girls and having presence of high female ratio as compared to the male population. 
• On the basis of end user, the central precocious puberty (CPP) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2020, hospitals segment is expected to dominate the central precocious puberty (CPP) treatment market with 52.58% market share as the hospitals are the first place for the diagnosis and treatment of CPP.

The hospitals centers segment will dominate the end user segment of the central precocious puberty (CPP) treatment market

The hospitals centers segment will emerge as the dominating segment end user segment.  This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

• On the basis of distribution channel, the central precocious puberty (CPP) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2020, direct tender segment is expected to dominate the central precocious puberty (CPP) treatment market with 48.72% market share as the drugs used for the CPP treatment can be procured through direct tender on reasonable price and the patients receive treatment for prolonged period of time.

The direct tender segment will dominate the distribution channel segment of the central precocious puberty (CPP) treatment market

The direct tender segment will emerge as the dominating segment under distribution channel with approximately 49.00% market share. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Ipsen Pharma (France), Arbor Pharmaceuticals (U.S.), Tolmar Pharmaceuticals, Inc. (U.S.), GP Pharm (Spain), Debiopharm (Switzerland), DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Endo International plc (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.)

Market Development

• In April 2019, Ipsen Pharma acquired Clementia Pharmaceuticals, a company focused on manufacturing of medicines for rare disease. This acquisition helped the company to strengthen its market for rare disease treatment involving central precocious puberty (CPP) treatment
• In January 2019, Takeda Pharmaceutical Company Limited completed the acquisition of Shire plc, which is involved in manufacturing of medicines for the treatment of various types of rare diseases such as central precocious puberty (CPP). This acquisition has helped the company to strengthen its product portfolio with the addition of new medicines used for treatment of central precocious puberty (CPP)
• In June 2019, Ipsen Pharma went under strategic partnership with Debiopharm for Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for treatment of central precocious puberty (CPP) in children. This strategic partnership helped the company to maintain a continuous product access to patients

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

As per Data Bridge Market Research analysis:

North America is the dominant region in central precocious puberty (CPP) treatment market during the forecast period 2020 - 2027

North America dominates the central precocious puberty (CPP) treatment market because of the well-established healthcare infrastructure in this region. Additionally, growing focus of major key players on novel technology will further propel the market's growth rate in this region.

Asia-Pacific is estimated to be the fastest growing region in central precocious puberty (CPP) treatment market the forecast period 2020 - 2027

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to growing incidences of obesity and rising healthcare expenditure in this region.

COVID-19 Impact

Private healthcare businesses, among others, were impacted by the COVID-19 outbreak and ensuing lockdown in various countries. The entire healthcare supply chain had been hampered by the COVID-19 epidemic because of the intense lockdown in some areas. The COVID-19 outbreak has had a three-fold impact on the economies of several nations around the world: it has directly impacted supply and demand, disrupted distribution channels, and had an economic impact on businesses and financial markets. Manufacturing companies associated with central precocious puberty project the COVID-19 pandemic to have a negative effect on the growth of the global central precocious puberty market during the forecast period due to a decrease in the supply of raw materials and pharmaceutical drugs.

For more detailed information about the central precocious puberty (CPP) treatment on market report, click here – https://www.databridgemarketresearch.com/reports/global-central-precocious-puberty-cpp-treatment-market